natgillin/translations-raw huggingface dataset:
Discontinuation of filgrastim therapy usually results in a 50 % decrease in circulating neutrophils within 1 to 2 days, with a return to normal levels in 1 to 7 days. 
Pri prekidu primjene filgrastima broj neutrofila u perifernoj krvi obično se za 1 do 2 dana smanji za 50 %, a 1 do 7 dana nakon toga ponovno se normalizira.
Biograstim 30 MIU/0.5 mL: Each pre-filled syringe contains 30 million international units [MIU] (300 microgram) of filgrastim in 0.5 mL solution. 
Biograstim 30 MIU/0,5 ml otopina za injekciju ili infuziju: Jedna napunjena štrcaljka sadrži 30 milijuna internacionalnih jedinica [MIU] (300 mikrograma) filgrastima u 0,5 ml otopine.
Monitoring of bone density may be indicated in patients with underlying osteoporotic bone diseases who undergo continuous therapy with filgrastim for more than 6 months. 
U bolesnika s osteoporoznim bolestima kosti u podlozi, koji primaju filgrastim duže od 6 mjeseci, može biti indicirano praćenje gustoće kosti.
Patients who have undergone very extensive prior myelosuppressive therapy may not show sufficient mobilisation of PBPC to achieve the recommended minimum yield (2.0 x 10 
U bolesnika koji su prethodno primali ekstenzivnu mijelosupresijsku terapiju, mobilizacija progenitorskih stanica periferne krvi možda neće biti dovoljna da se dobije preporučeni minimalni broj stanica (2,0 x 106 CD34+ stanica/kg) ili da se u jednakom stupnju ubrza oporavak broja trombocita.
The effects of filgrastim on neutropenia due to bone marrow-infiltrating infection or malignancy have not been well established. 
Učinci filgrastima na neutropeniju prouzročenu infekcijom ili zloćudnom bolešću koja infiltrira koštanu srž nisu ispitani.
It is unknown whether filgrastim passes over to the breast milk. 
Nije poznato izlučuje li se filgrastim u majčino mlijeko.
Very common (may affect more than 1 in 10 people): - elevated levels of some liver or blood enzymes; high blood levels of uric acid; - feeling sick; vomiting; - chest pain. 
Vrlo često (mogu se javiti u više od 1 na 10 osoba): - povišene razine nekih jetrenih enzima ili krvnih enzima; visoka razina mokraćne kiseline u krvi; - mučnina; povraćanje; - bol u prsima.
Rheumatoid arthritis exacerbation 
Egzacerbacija reumatoidnog artritisa
Following established chemotherapy for solid tumours, lymphomas and lymphoid leukaemias, it is expected that the duration of treatment required to fulfil these criteria will be up to 14 days. 
Očekuje se da će primjena filgrastima nakon dokazano citotoksične kemoterapije za solidne tumore, limfome i limfocitne leukemije trajati do 14 dana.
It is quite normal to have a number of courses of Biograstim treatment. 
Uobičajeno je uzimati Biograstim u više navrata.
Once the neutrophil nadir has been passed the daily dose of filgrastim should be titrated against the neutrophil response as follows: 
Nakon što prođe najizraženije smanjenje broja neutrofila, dnevnu dozu filgrastima treba titrirati prema odgovoru neutrofila, prema niže navedenoj shemi.
In normal donors, pulmonary adverse events (haemoptysis, pulmonary haemorrhage, lung infiltration, dyspnoea and hypoxia) have been reported in postmarketing experience (see section 4.4). 
U normalnih davatelja, u postmarketinškom periodu zabilježene su plućne nuspojave (hemoptiza, plućna hemoragija, infiltracija pluća, dispneja i hipoksija) (vidjeti dio 4.4).
Undesirable effects related to filgrastim therapy in SCN patients have been reported and for some their frequencies tend to decrease with time. 
U bolesnika s teškom kroničnom neutropenijom prijavljivane su nuspojave povezane s primjenom filgrastima; učestalost nekih s vremenom se smanjivala.
The usual dose is 0.5 million international units (MIU) per kilogram of bodyweight each day. 
Uobičajena doza je 0,5 milijuna internacionalnih jedinica (engl. million international units, MIU) po kilogramu tjelesne težine svaki dan.
Clearance of filgrastim has been shown to follow first-order pharmacokinetics after both subcutaneous and intravenous administration. 
Pokazalo se da klirens filgrastima i nakon supkutane i nakon intravenske primjene slijedi obrazac farmakokinetičkih procesa prvog reda.
Each pre-filled syringe contains 30 million international units [MIU] (300 microgram) of filgrastim in 0.5 mL (60 MIU/mL, 600 microgram/mL). 
Jedna napunjena štrcaljka sadrži 30 milijuna internacionalnih jedinica [MIU] (300 mikrograma) filgrastima u 0,5 ml otopine (60 MIU /ml, 600 mikrograma/ml).
Your doctor will continue to test your blood regularly and will recommend the best dose for you. 
Liječnik će nastaviti pratiti Vašu krvnu sliku i odrediti koja je doza za Vas najbolja.
In patients with known bone marrow-infiltrating infections or malignancy, consider appropriate therapy for treatment of the underlying condition in addition to administration of filgrastim for treatment of neutropenia. 
U bolesnika s poznatom infiltracijom uzročnicima infekcije ili zloćudnom bolešću valja, povrh primjene filgrastima za ispravljanje leukopenije, razmotriti i primjenu prikladnog lijeka za liječenje stanja u podlozi.
Capillary leak syndrome* 
Sindrom povećane propusnosti kapilara*
For the mobilisation of PBPC in normal donors prior to allogeneic peripheral blood progenitor cell transplantation 
Za mobilizaciju progenitorskih stanica periferne krvi u zdravih davatelja prije presađivanja alogeničnih progenitorskih stanica periferne krvi
Filgrastim should be diluted in 20 mL of glucose 50 mg/mL (5 %) solution for infusion (see section 6.6 for instructions on dilution). 
Filgrastim treba razrijediti u 20 ml 50 mg/ml (5 %) otopine glukoze za infuziju (za upute o razrjeđivanju vidjeti dio 6.6).
Long-term treatment with Biograstim may be required to maintain a normal number of white cells in your blood. 
Možda će za održavanje normalnog broja bijelih stanica u krvi biti nužna dugotrajnija primjena lijeka Biograstim.
Biograstim and bone marrow transplantation 
Biograstim i presađivanje koštane srži
Regular monitoring of platelet count and haematocrit is recommended. 
Preporučuju se redovite kontrole hematokrita i broja trombocita.
The first dose of filgrastim should not be administered less than 24 hours following cytotoxic chemotherapy. 
Prva doza filgrastima smije se dati najranije 24 sata nakon citotoksične kemoterapije.
The recommended starting dose of filgrastim is 0.1 MIU (1 μg)/kg/day given daily by subcutaneous injection with titration up to a maximum of 0.4 MIU (4 μg)/kg/day until a normal neutrophil count is 
Preporučena početna doza je 0,1 MIU (1 μg)/kg/dan svakoga dana u supkutanoj injekciji, i može se titrirati do najviše 0,4 MIU (4 μg)/kg/dan, do postizanja normalnog broja neutrofila, koji će biti moguće i održavati (ABN > 2,0 x 109/l).
Long-term treatment with Biograstim is required for neutropenia. 
Pri neutropeniji je nužna dugotrajnija primjena lijeka Biograstim.
Common (may affect up to 1 in 10 people): - reduction in blood platelets, which increases risk of bleeding or bruising; - headache; - diarrhoea; - enlargement of the liver; - hair loss; inflammation of blood vessels, often with skin rash; pain at the site of injection; rash; - loss of calcium from the bones; joint pain. 
Često (mogu se javiti do 1 na 10 osoba): - smanjeni broj trombocita u krvi, zbog čega se može povećati mogućnost pojave krvarenja ili modrica; - glavobolja; - proljev; - povećanje jetre; - ispadanje kose; upala krvnih žila, često uz kožni osip;bol na mjestu injekcije; osip; - gubitak kalcija iz kostiju; bol u zglobovima.
The degree of variation between individual patients and between laboratory assays of CD34 
Stupanj varijacije između pojedinih bolesnika i između laboratorijskih metoda brojenja CD34+ stanica pokazuje da je izravna usporedba između ispitivanja teška.
9/L prior to leukapheresis; in general apheresis should not be performed if platelets < 100 x 10 
Treba li obaviti više od jedne leukafereze, nužan je poseban oprez u davatelja s trombocitima < 100 x 109/l prije leukafereze; aferezu općenito ne treba izvoditi ako su trombociti < 75 x 109/l.
For the mobilisation of PBPC in patients undergoing myelosuppressive or myeloablative therapy followed by autologous peripheral blood progenitor cell transplantation 
Za mobilizaciju progenitorskih stanica periferne krvi u bolesnika s presađenim autolognim progenitorskim stanicama periferne krvi nakon mijelosupresijske ili mijeloablacijske terapije
9/L, and a history of severe or recurrent infections, long absolute neutrophil count (ANC) of ≤ 0.5 x 10 term administration of Biograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events. 
U bolesnika, djece i odraslih, s teškom kongenitalnom cikličkom ili idiopatskom neutropenijom i apsolutnim brojem neutrofila (ABN) ≤ 0,5 x 109/l, kao i s teškim ili rekurentnim infekcijama u anamnezi, dugotrajna primjena Biograstim se koristi za povećanje broja neutrofila i za smanjenje incidencije i skraćivanje trajanja događaja povezanih s infekcijama.
Isolated cases of sickle cells crises have been reported in patients with sickle cell disease (see section 4.4). 
U bolesnika s anemijom srpastih stanica (vidjeti dio 4.4) prijavljeni su izolirani slučajevi kriza srpastih stanica.
- The active substance is filgrastim. 
Što Biograstim sadrži - Djelatna tvar je filgrastim.
Elevated alkaline phosphatase, elevated LDH, elevated uric acid 
Povišena alkalna fosfataza, povišena LDH, povišena mokraćna kiselina
For infusions, filgrastim should be diluted in 20 mL of glucose 50 mg/mL (5 %) solution for infusion (see section 6.6 for instructions on dilution). 
Za infuziju je filgrastim potrebno razrijediti u 20 ml 50 mg/ml (5 %) otopine glukoze za infuziju (za upute o razrjeđivanju vidjeti dio 6.6).
Established cytotoxic chemotherapy 
Utvrđeni protokol citotoksične kemoterapije
The most commonly reported undesirable effect was mild to moderate transient musculo-skeletal pain. 
Najčešće prijavljivana nuspojava bila je blaga do umjerena, prolazna bol u mišićno-koštanom sustavu.
Talk to your doctor or nurse that you are treated with Biograstim if you are undergoing bone-imaging. 
U slučaju snimanja kostiju recite liječniku ili medicinskoj sestri da se liječite Biograstimom.
Biograstim 30 MIU/0.5 mL solution for injection or infusion Filgrastim 
Biograstim 30 MIU/0,5 ml otopina za injekciju ili infuziju filgrastim
Subcutaneous use and intravenous use. 
Za potkožnu primjenu i primjenu u venu.
Packs containing 1, 5 or 10 pre-filled syringes with 0.5 mL solution or multipacks containing 10 (2 packs of 5) pre-filled syringes with 0.5 mL solution. 
Pakiranje sadrži 1, 5 ili 10 napunjenih štrcaljki s 0,5 ml otopine ili višestruka pakiranja s 10 (2 pakiranja od 5) napunjenih štrcaljki s 0,5 ml otopine.
The use of filgrastim-mobilised PBPCs has been shown to reduce the depth and duration of thrombocytopenia following myelosuppressive or myeloablative chemotherapy. 
Pokazalo se da progenitorske stanice periferne krvi, mobilizirane filgrastimom, smanjuju jačinu i skraćuju trajanje trombocitopenije nakon mijelosupresijske ili mijeloablacijske kemoterapije.
Special precautions in sickle cell disease 
Posebne mjere opreza pri bolesti srpastih stanica
Packs containing 1, 5 or 10 pre-filled syringes with 0.8 mL solution or multipacks containing 10 (2 packs of 5) pre-filled syringes with 0.8 mL solution. 
Pakiranje sadrži 1, 5 ili 10 napunjenih štrcaljki s 0,8 ml otopine ili višestruka pakiranja s 10 (2 pakiranja od 5) napunjenih štrcaljki s 0,5 ml otopine.
EU/1/08/450/001 1 pre-filled syringe EU/1/08/450/002 5 pre-filled syringes EU/1/08/450/004 10 pre-filled syringes EU/1/08/450/009 5 pre-filled syringes with safety device 
EU/1/08/450/001 1 napunjena štrcaljka EU/1/08/450/002 5 napunjenih štrcaljki EU/1/08/450/004 10 napunjenih štrcaljki EU/1/08/450/009 5 napunjenih štrcaljki sa zaštitom za iglu
Haematuria/proteinuria occurred in a small number of patients. 
U malog broja bolesnika javila se hematurija/proteinurija.
9/L during the treatment period the dose of filgrastim should be reescalated according to the above steps 
Smanji li se ABN tijekom trajanja terapije na < 1,0 x 109/l, dozu filgrastima treba ponovno povećavati u skladu s gornjom shemom.
Daily dosing with filgrastim should continue until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range. 
Filgrastim treba davati svakodnevno, sve dok ne prođe razdoblje očekivanih najnižih vrijednosti broja neutrofila i dok se njihov broj ne normalizira.
cannot be estimated from the available data Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. 
U svakoj skupini prema učestalosti, nuspojave su navedene silaznim slijedom prema ozbiljnosti.
However, in view of the potential risks associated with severe leukocytosis, a white blood cell count should be performed at regular intervals 
No sa stajališta mogućih rizika povezanih s jakom leukocitozom, pri terapiji filgrastimom potrebno je u redovitim vremenskim razmacima, provjeravati broj leukocita.
In normal stem cell donors 
U zdravih davatelja matičnih stanica
9/L) was observed in 41 % of donors and transient 9/L) following filgrastim and leukapheresis was observed in thrombocytopenia (platelets < 100 x 10 
Leukocitoza (leukociti > 50 x 109/l) je uočena u 41 %, a prolazna trombocitopenija (trombociti < 100 x 109/l) u 35 % davatelja nakon primjene filgrastima i leukafereze.
Sixty-five percent of the patients studied in the SCN trial programme were under 18 years of age. 
Pedijatrijska primjena u bolesnika s teškom kroničnom neutropenijom i u onkoloških bolesnika Šezdeset pet posto bolesnika uključenih u program ispitivanja teške kronične neutropenije bilo je mlađe od 18 godina.
Special precautions in normal donors undergoing peripheral blood progenitor cell mobilisation 
Posebne mjere opreza u zdravih davatelja u kojih se obavlja mobilizacija progenitorskih stanica periferne krvi
EU/1/08/450/005 1 pre-filled syringe EU/1/08/450/006 5 pre-filled syringes EU/1/08/450/008 10 pre-filled syringes EU/1/08/450/010 5 pre-filled syringes with safety device 
EU/1/08/450/005 1 napunjena štrcaljka EU/1/08/450/006 5 napunjenih štrcaljki EU/1/08/450/008 10 napunjenih štrcaljki EU/1/08/450/010 5 napunjenih štrcaljki sa zaštitom za iglu
Vascular disorders, including veno-occlusive disease and fluid volume disturbances, have been reported occasionally in patients undergoing high dose chemotherapy followed by autologous bone marrow transplantation. 
U bolesnika kojima je presađena koštana srž nakon prethodne primjene velikih doza kemoterapije bilo je povremenih prijava poremećaja krvnih žila, uključujući venookluzivnu bolest i poremećaje volumena tekućine.
Dispose of syringes with safety device as instructed by your doctor, nurse or pharmacist. 
Štrcaljku zbrinite kako su Vam objasnili liječnik, medicinska sestra ili ljekarnik.
Biograstim 48 MIU/0.8 mL solution for injection or infusion Filgrastim 
Biograstim 48 MIU/0,8 ml otopina za injekciju ili infuziju filgrastim
Box for the prescribed dose 
Prostor za preporučeno doziranje
Allergic Reactions: Allergic-type reactions, including anaphylaxis, skin rash, urticaria, angioedema, dyspnoea and hypotension, occurring on initial or subsequent treatment, have been reported in patients receiving filgrastim. 
Alergijske reakcije: U bolesnika koji su primali filgrastim prijavljivane su alergijske reakcije na početku primjene ili pri kasnijoj primjeni, uključujući anafilaksiju, kožni osip, urtikariju, angioedem, dispneju i hipotenziju.
Special precautions in patients undergoing peripheral blood progenitor cell mobilisation Mobilisation 
Posebne mjere opreza u bolesnika u kojih se obavlja mobilizacija progenitorskih stanica periferne krvi
Transient cytogenic modifications have been observed in normal donors following G-CSF use. 
U zdravih davatelja koji su primali G-CSF uočene su prolazne citogenetske promjene.
Solution for injection or infusion Multipack: 10 (2 packs of 5) pre-filled syringes containing 0.8 mL. 
Višestruko pakiranje: 10 (2 pakiranja od 5) napunjenih štrcaljki koje sadrže 0,8 ml.
Alopecia, skin rash Sweet's syndrome, cutaneous vasculitis 
Sweetov sindrom, kožni vaskulitis
Each mL of solution for injection or infusion contains 60 million international units [MIU] (600 µg) of filgrastim. 
KVALITATIVNI I KVANTITATIVNI SASTAV Jedan ml otopine za injekciju ili infuziju sadrži 60 milijuna internacionalnih jedinica [MIU] (600 μg) filgrastima.
The following undesirable effects and their frequencies have been observed under treatment with filgrastim based on published information. 
Nuspojave prema dosad objavljenim podacima, i njihova učestalost pri primjeni filgrastima niže su navedene.
The duration of fever was not reduced in patients undergoing myeloablative therapy followed by bone marrow transplantation. 
U bolesnika kojima je nakon mijeloablacijske terapije presađena koštana srž nije se skratilo vrijeme trajanja vrućice.
No effect was observed on the fertility of male and female rats or gestation in rats. 
Filgrastim se nije pokazao teratogenim u štakora i kunića.
Solution for injection or infusion Multipack: 10 (2 packs of 5) pre-filled syringes containing 0.5 mL. 
Višestruko pakiranje: 10 (2 pakiranja od 5) napunjenih štrcaljki koje sadrže 0,5 ml.
When the response has been obtained, the reached and can be maintained at more than 1.5 x 10 minimal effective dose to maintain this level should be established. 
Nakon što se postigne odgovor, treba odrediti minimalnu učinkovitu dozu za održavanje te razine neutrofila.
Biograstim 30 MIU/0.5 mL solution for injection or infusion 
NAZIV LIJEKA Biograstim 30 MIU/0,5 ml otopina za injekciju ili infuziju
Subsequently the dose may be 
OD LIJEKA AKO JE POTREBNO
2/day (4.0 to 8.4 μg/kg/day) was used. 
U randomiziranim kliničkim ispitivanjima davala se supkutano doza od 23 MIU (230 μg)/m2/dan (4,0 do 8,4 μg/kg/dan).
During long term use, cutaneous vasculitis has been reported in 2 % of SCN patients. 
Tijekom dugotrajne primjene u 2 % bolesnika s teškom kroničnom neutropenijom prijavljen je vaskulitis.
Contents of the pack and other information What Biograstim contains 
Sadržaj pakiranja i druge informacije
A faster schedule of dose escalation may be considered in patients presenting with and 10 x 10 severe infections. 
U bolesnika s teškim infekcijama može se razmotriti brže prilagođavanje doze.
Exacerbation of rheumatoid arthritis has been observed in individual cases. 
Bilo je pojedinačnih slučajeva egzacerbacije reumatoidnog artritisa.
In patients treated with myeloablative therapy followed by bone marrow transplantation 
Bolesnici s presađenom koštanom srži i prethodnom mijeloablacijskom terapijom
Very rare (may affect up to 1 in 10,000 people): - painful, raised, plum-coloured sores on the limbs and sometimes the face and neck with fever 
Rijetko (mogu se javiti do 1 na 1000 osoba): - vaskularni poremećaji, koji mogu uzrokovati bol, crvenilo i oticanje udova.
There was a low frequency (approximately 3 %) of myelodysplastic syndromes (MDS) or leukaemia in clinical trial patients with SCN treated with filgrastim. 
U kliničkim ispitivanjima bolesnika s teškom kroničnom neutropenijom koji su primali filgrastim, malom su se učestalošću (oko 3 %) javljali mijelodisplastični sindrom (MDS) ili leukemija.
Consideration should be given to intermittent cessation or decreasing the dose of filgrastim in patients who develop thrombocytopenia, i.e. platelets consistently < 100,000/mm 
U bolesnika koji razviju trombocitopeniju, tj. kada je broj trombocita kontinuirano < 100 000/mm3, potrebno je razmotriti mogućnost povremenih prekida primjene ili smanjenja doze filgrastima.
(Sweet's syndrome); inflammation of blood vessels, often with skin rash; - worsening of rheumatic conditions; - pains or difficulties in passing urine. 
- pojava bolnih, uzdignutih, modro obojenih žarišta po udovima te katkada i po licu i vratu praćenih vrućicom (Sweetov sindrom); upala krvnih žila, često uz kožni osip; - pogoršanje reumatskih stanja; - bolno ili otežano mokrenje.
Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive medicinal products. 
Rizik povezan s povećanim dozama mijelosupresijskih lijekova Primjena filgrastima samog ne znači da će se spriječiti pojava trombocitopenije i anemije izazvana primjenom mijelosupresijskih lijekova.
Biograstim 48 MIU/0.8 mL solution for injection or infusion 
NAZIV LIJEKA Biograstim 48 MIU /0,8 ml otopina za injekciju ili infuziju
These autologous PBPCs may be harvested and infused after high-dose cytotoxic therapy, either in place of or in addition to bone marrow transplantation. 
Autologne progenitorske stanice periferne krvi mogu se izdvojiti, i ponovno dati infuzijom nakon velikih doza citotoksične kemoterapije, bilo umjesto presađivanja koštane srži, bilo zajedno s njim.
SPECIAL STORAGE CONDITIONS 
Posebne populacije
Rare: 
Rijetko
Filgrastim 
Proljev
Spleen disorder 
Poremećaj slezene
Long-term daily administration is required to maintain an adequate neutrophil count. 
Za održavanje primjerenog broja neutrofila nužna je dugotrajna primjena lijeka.
In peripheral blood progenitor cell mobilisation in normal donors 
Pri mobilizaciji progenitorskih stanica u perifernoj krvi zdravih davatelja
Leukocytosis, thrombocytopenia Spleen disorder 
Leukocitoza, trombocitopenija
Solution for injection or infusion 5 pre-filled syringes containing 0.8 mL. 
5 napunjenih štrcaljki koje sadrže 0,8 ml.
Biograstim and peripheral blood stem cell mobilisation If you are donating stem cells for yourself, the usual dose is 0.5 million to 1 million international units (MIU) per kilogram bodyweight each day. 
Ako ćete primiti vlastite matične stanice, uobičajena doza je 0,5 milijuna do 1 milijun internacionalnih jedinica [MIU] po kilogramu tjelesne težine na dan.
≥ 1/1,000 to < 1/100 
≥1/100 do <1/10, Manje česte: ≥1/1000 do <1/100, Rijetke:
EU/1/08/450/007 2 x 5 pre-filled syringes 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/08/450/007 2 x 5 napunjenih štrcaljki
cells/kg is based on published experience resulting in adequate haematologic reconstitution. 
Preporuka o minimalnom prinosu od 2,0 x 106 CD34+ stanica/kg temelji se na dosad objavljenim iskustvima, u kojima se postigla primjerena hematološka rekonstitucija.
Excipients 
Učestalost
In severe chronic neutropenia patients 
Bolesnici s teškom kroničnom neutropenijom
Solution for injection or infusion 5 pre-filled syringes containing 0.5 mL. 
5 napunjenih štrcaljki koje sadrže 0,5 ml.
EU/1/08/450/003 2 x 5 pre-filled syringes 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/08/450/003 2 x 5 napunjenih štrcaljki
Special precautions in recipients of allogeneic PBPC mobilised with filgrastim 
Posebne mjere opreza u primatelja alogeničnih progenitorskih stanica periferne krvi mobiliziranih filgrastimom
Chest pain, musculoskeletal pain 
Bol u prsištu, bol u mišićnokoštanom sustavu
In patients with HIV infection For reversal of neutropenia 
Bolesnici s HIV-infekcijom
Prior to allogeneic PBPC transplantation, use of filgrastim for the mobilisation of PBPC in normal donors allows a collection of 4 x 10 
Primjenom filgrastima u zdravih davatelja u svrhu mobilizacije progenitorskih stanica periferne krvi prije alogenog presađivanja tih stanica, u većine se davatelja dvjema leukaferezama prikupi 4 x 106 CD34+ stanica po kg tjelesne težine davatelja.
Uncommon 
Kronični
Then, if ANC remains > 1.0 x 10 
Potom, ako je ukupni broj neutrofila >1,0x109/l tijekom najmanje 3 uzastopna dana
Transient, minor increases in alkaline phosphatase, LDH, SGOT (serum glutamic oxaloacetic transaminase) and uric acid have been reported in normal donors receiving filgrastim; these were without clinical sequelae. 
U zdravih davatelja koji su primali filgrastim bilo je prijava prolaznog i slabog povišenja alkalne fosfataze, LDH, AST i mokraćne kiseline; to nije imali nikakvih kliničkih posljedica.
6.6 Special precautions for disposal and other handling 
4.4 Posebna upozorenja i mjere opreza pri uporabi
4.8 Undesirable effects Summary of the safety profile 
Sažetak sigurnosnog profila
Very rare events of cutaneous vasculitis have been reported in patients treated with filgrastim. 
U bolesnika koji su primali filgrastim bilo je vrlo rijetkih prijava kožnog vaskulitisa.